Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing non-engineered T cell therapies targeting multiple tumor antigens. Its proprietary MAR-T platform aims to treat hematological malignancies and solid tumors by expanding natural tumor-specific T cells, minimizing tumor escape and adverse effects. The company’s products include autologous and off-the-shelf therapies, with a focus on lymphoma, pancreatic cancer, AML, and MDS, leveraging broad-spectrum, cost-effective immunotherapies.
This description was generated via AI from an annual report. Updated about 1 year ago.